Next Article in Journal
Advancing Academic Cancer Clinical Trials Recruitment in Canada
Previous Article in Journal
Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 28
Issue 4
10.3390/curroncol28040247
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

by
Erica S. Tsang
1,
Gayle Funk
2,
Janet Leung
2,
Grace Kalish
2 and
Hagen F. Kennecke
3,*
1
Division of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada
2
Virginia Mason Cancer Institute, Seattle, WA 98101, USA
3
Providence Cancer Institute & Chiles Research Institute, Portland, OR 97213, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(4), 2823-2829; https://doi.org/10.3390/curroncol28040247
Submission received: 22 April 2021 / Revised: 24 May 2021 / Accepted: 2 June 2021 / Published: 26 July 2021
(This article belongs to the Section Gastrointestinal Oncology)
Browse Figures
Versions Notes

Abstract

Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs). Patients are at risk of a PRRT-induced catecholamine crisis, and standard guidelines regarding the prevention and management of infusion reactions are lacking. In this case series, the institutional experience of five sequential patients with metastatic PCCs and PGLs receiving PRRT on an outpatient basis is described, of which four had symptomatic tumors and three had a high burden of disease. All patients with symptomatic tumors were treated with preventive management prior to the initiation of PRRT, and no infusion reactions or catecholamine crises were documented. PRRT may be delivered safely on an outpatient basis for patients with metastatic PCCs and PGLs with the involvement of an interdisciplinary team.
Keywords: pheochromocytoma; paraganglioma; peptide receptor radionuclide therapy pheochromocytoma; paraganglioma; peptide receptor radionuclide therapy

Share and Cite

MDPI and ACS Style

Tsang, E.S.; Funk, G.; Leung, J.; Kalish, G.; Kennecke, H.F. Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT. Curr. Oncol. 2021, 28, 2823-2829. https://doi.org/10.3390/curroncol28040247

AMA Style

Tsang ES, Funk G, Leung J, Kalish G, Kennecke HF. Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT. Current Oncology. 2021; 28(4):2823-2829. https://doi.org/10.3390/curroncol28040247

Chicago/Turabian Style

Tsang, Erica S., Gayle Funk, Janet Leung, Grace Kalish, and Hagen F. Kennecke. 2021. "Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT" Current Oncology 28, no. 4: 2823-2829. https://doi.org/10.3390/curroncol28040247

APA Style

Tsang, E. S., Funk, G., Leung, J., Kalish, G., & Kennecke, H. F. (2021). Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT. Current Oncology, 28(4), 2823-2829. https://doi.org/10.3390/curroncol28040247

Article Metrics

Back to TopTop